Profile of Head and Neck Cancer Patients at Department of Otorhinolaringology-Head and Neck Surgery Dr. Hasan Sadikin General Hospital Bandung

Rakhmawulan, Inez Aulia; Dewi, Yussy Afriani; Nasution, Nursiah

doi:10.15850/amj.v2n4.630

Cited by 3 publications

(3 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The majority of HNC cancer patients who come to the hospital are at locally advanced stage. The proportion of those with stage III reaches 24-25% and stage IV 44-54% [3,4]. Progression-free survival (PFS) and overall survival (OS) are useful outcome measures in evaluating HNC patients.…”

mentioning

confidence: 99%

Factors that Influence 2-Year Progression-Free Survival Among Head and Neck Cancer Patients

Irawan

Benbella

Rachman

et al. 2021

J Epidemiol Glob Health

View full text Add to dashboard Cite

Objectives The majority of patients with head and neck cancer (HNC) come to the hospital at advanced stages. This research was conducted to determine the mortality, 2-year progression-free survival (PFS) and factors that influenced PFS of HNC patients. Methods A retrospective cohort study was conducted among locally advanced HNC patients who underwent chemoradiation for the first time at RSCM from January 2015 to December 2017. Data were retrieved through medical records. Laboratory data were taken 2–4 weeks prior and 2–4 weeks after chemoradiation. PFS observation started from the first day of chemoradiation until disease progression or death. PFS data were recorded in two groups: ≤ 2 years and > 2 years. The Chi-square test was used for bivariate analysis with the Fischer-exact test as an alternative. Variables will be further tested using multivariate logistic regression tests. Results Among 216 subjects, there were 103 (47.69%) patients who did not reach overall survival (OS) > 2 years. There were 108 (50%) patients who had PFS > 2 years. Based on the results of multivariate analysis, it was found that smoking, hemoglobin level ≤ 12 g/dl, ECOG (Eastern Cooperative Oncology Group) 1–2, and negative therapeutic response were associated with poor PFS. Hazard ratio (HR) for 2-year PFS for Brinkman index > 250 was 1.36 (95% CI 0.93–2.00; p = 0.02); HR for Hb ≤ 12 g/dl was 1.65 (95% CI 1.13–2.42; p = 0.01); HR for ECOG 1–2 was 4.05 (95% CI 1.49–11.00; p < 0.01); and HR for negative therapeutic response was 2.37 (95% CI 1.43–3.94; p < 0.01). Conclusion Mortality of HNC patients within 2 years is 47.69%, with a 2-year PFS reaching 50%. Cigarette smoking, low hemoglobin levels, poor performance status, and negative therapeutic response (non-responders) negatively affect the 2-year PFS.

show abstract

mentioning

confidence: 99%

Factors that Influence 2-Year Progression-Free Survival Among Head and Neck Cancer Patients

Irawan

Benbella

Rachman

et al. 2021

J Epidemiol Glob Health

View full text Add to dashboard Cite

show abstract

“…12 Also in older patients who are exposed to carcinogens for longer, there is an accumulation of cells, decreased DNA repair function, and decreased immune system. 14 The results show that alcohol consumption can worsen the condition and lower the survival of patients with laryngeal carcinoma. The study of Abrahao et al supports this, which states that 5-year survival in laryngeal and hypopharyngeal carcinoma patients with drinking habits before and after being diagnosed with carcinoma were 57.3% and 58.8% respectively whereas in patients who do not were 66.7%.…”

Section: Discussionmentioning

confidence: 96%

An Analytical Study: Survival Rate of Laryngeal Carcinoma Patients Among Indonesian Population

Bawa¹,

Aroeman²,

Dewi³

2021

PJMHS

Self Cite

View full text Add to dashboard Cite

Introduction: Laryngeal carcinoma is a malignant squamous metaplasia of the overlying epithelial surface of larynx. Several factors are believed to affect the survival of laryngeal carcinoma. This study aims to identify the survival of patients with laryngeal carcinoma. Materials and Methods: This was a retrospective cohort study using Cox Regression analysis for the survival analysis design. Patients were included if they were diagnosed with laryngeal cancer, had radiotherapy, chemotherapy, surgery or combination therapy and had a complete medical record. Data were collected retrospectively from medical records, such as smoking, alcohol consumption, genetic, tumor location, stadium, and therapy. Result: The results shows that from the 149 patients with laryngeal carcinoma who came to Head and Neck Surgery oncology outpatient clinic and had received therapy in the period January 2009 to December 2014, it was founded that smoking, alcohol, genetic, staging, surgery, and chemotherapy had a significant relationship to the laryngeal carcinoma survival (p value <0.05). While the location of the tumor and radiation did not show a significant relationship (p value> 0.05). Based on multivariable analysis of Cox Regression obtained smoking, alcohol, and surgery which provides a significant influence on survival. Patients who smoke have a risk of death 23.9 times. Suffering from consuming alcohol has a risk 2.41 times of death. Patients who do surgery can reduce the risk of death about 54%. Conclusion: The 5-year survival of patients with laryngeal carcinoma is 56.4%. Keywords: Patient Factors, Prognostic Factors, Tumor Factors, Laryngeal Carcinoma, Survival

show abstract

“…The initial symptoms of head and neck tumors are typical, only resembling upper respiratory tract infections, stomatitis, voice changes, and nasal congestion. 11 Human papillomavirus has been found in premalignant tumors and malignant tumors of the head and neck. Malignancy occurs due to HPV infection mediated by E6 and E7 proteins expression, inhibiting tumor suppressor gene pathways by inactivating TP53.…”

Section: Discussionmentioning

confidence: 99%

IgG levels in Human Papillomavirus Infection Associated with Clinical Stage of Head and Neck Squamous Cell Carcinoma

Dewi

Permana

Yudhiono

2021

amj

View full text Add to dashboard Cite

Background: Head and neck squamous cell carcinoma (HNSCC) is an invasive neoplasm of epithelial tissue in the head and neck and one of the etiologies of HNSCC is human papillomavirus (HPV) which may be associated with the clinical stage of HNSCC. HPV infection in squamous cell epithelium produces specific IgG antibodies against HPV. IgG titer of HPV can help identify patients who are at risk for HPVrelated cancers. This study aimed to explore the association between IgG titer of HPV with the clinical stages of HNSCC. Methods: The design of this study was analytic cross sectional, conducted at the Outpatient Clinic of Otorhinolaryngology-Head and Neck Surgery, Division of Oncology, Dr. Hasan Sadikin General Hospital Bandung period September-December 2017. Patients with HNSCC were recruited, and history was taken. Furthermore, histopathologic examination and HPV IgG serology examination were performed using the ELISA method. The HPV IgG levels were compared by stage and data were analyzed using the Shapiro Wilks test and Unpaired T test. Results:The HPV IgG was high in 75% (n=21) of HNSCC patients in the advanced stage and low in 25% (n=7) of patients in the early stage. There was a significant relationship between HPV IgG titer and early and advanced stage of HNSCC (p=0.001). Conclusions:The HPV IgG titer is related to the clinical stage of HNSCC indicating that the higher the HPV IgG level, the more advanced the clinical stage. Further study is needed to explore HPV IgG levels as a prognostic marker in HNSCC.

show abstract

Profile of Head and Neck Cancer Patients at Department of Otorhinolaringology-Head and Neck Surgery Dr. Hasan Sadikin General Hospital Bandung

Cited by 3 publications

References 16 publications

Factors that Influence 2-Year Progression-Free Survival Among Head and Neck Cancer Patients

Factors that Influence 2-Year Progression-Free Survival Among Head and Neck Cancer Patients

An Analytical Study: Survival Rate of Laryngeal Carcinoma Patients Among Indonesian Population

IgG levels in Human Papillomavirus Infection Associated with Clinical Stage of Head and Neck Squamous Cell Carcinoma

Contact Info

Product

Resources

About